Xencor (XNCR) Non-Current Debt (2023 - 2026)
Xencor (XNCR) posted quarterly Non-Current Debt of $82.1 million for Q1 2026, down 19.36% year-over-year from $101.8 million in Q1 2025, and up 7.38% quarter-over-quarter from $76.5 million in Q4 2025.
Xencor (XNCR) Non-Current Debt (2023 - 2026) Analysis & Trends
Xencor (XNCR) has reported Non-Current Debt for 4 consecutive years, with $82.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt fell 19.36% year-over-year to $82.1 million; the TTM figure through Mar 2026 stood at $82.1 million (down 19.36% YoY), while the FY2025 annual figure was $76.5 million, down 33.59% from the prior year.
- Non-Current Debt grew to $82.1 million in Q1 2026 per XNCR's latest filing, from $76.5 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $161.8 million in Q4 2023 and bottomed at $76.5 million in Q4 2025.
- Historically, Non-Current Debt has averaged $114.0 million across 4 years, with a median of $108.5 million in 2024.
- Annual changes were most pronounced in 2025 — Non-Current Debt slumped 33.59% — and 2026, when it decreased 19.36%.
- Xencor's Non-Current Debt stood at $161.8 million in 2023, then declined by 28.81% to $115.2 million in 2024, then plunged by 33.59% to $76.5 million in 2025, then advanced by 7.38% to $82.1 million in 2026.
- Business Quant data shows XNCR's Non-Current Debt at $82.1 million in Q1 2026, $76.5 million in Q4 2025, and $87.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | 77.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.54 Mn |
| Mar 31, 2026 | 82.12 Mn |
| Dec 31, 2025 | 76.48 Mn |
| Sep 30, 2025 | 87.78 Mn |
| Jun 30, 2025 | 94.74 Mn |
| Mar 31, 2025 | 101.84 Mn |
| Dec 31, 2024 | 115.16 Mn |
| Sep 30, 2024 | 128.34 Mn |
| Jun 30, 2024 | 140.83 Mn |
| Mar 31, 2024 | 150.90 Mn |
| Dec 31, 2023 | 161.77 Mn |